Weekender 12/5/14

It’s hard to believe that we are entering the first weekend in December, which means a lot of activity on the business front – securing the last few product approvals, closing the books on some important deals – and bringing in the holidays.

No doubt it’s been a busy first week of December for New Jersey’s expanding life sciences industry, with plenty of stories making their way down the pipeline. A total of 28 biotech companies were on the list of 44 companies identified by the New Jersey Economic Development Authority (EDA) as sharing a total of $54 million under the State’s Technology Business Tax Certificate Transfer Program. NPS Pharma announced that the European Medicines Agency (EMA) has validated and initiated its review of the company’s marketing authorization application (MAA) for Natpar (known as Natpara in the US) for the treatment of Hypoparathyroidism. Levolta Pharmaceuticals posted Phase II results for patients with Osteoarthritis at the American College of Rheumatology Annual Meeting, while ADMA Biologics announced positive Phase III data for Primary Immune Deficiency Disease (PIDD) patients. Arno Therapeutics officially named a full-time CEO and the BASF Corporation gave NJ schools a $100K STEM grant, helping further the study of science for kids in grades K-12.

At the institutional level, Rowan University was certainly busy. The Rowan Innovation Venture Fund appointed a new Managing Director and Dr. Mark Byrne was named the new head of the Biomedical Engineering program.

Click here to read this week’s Weekender.